Table 4.

Odds of Switch From Injectable First-Line Treatment to a Higher-Efficacy Therapy^a in Patients With a Clinical Onset ≥2009 Applying Pretreatment sNfL Cut-offs 7.5, 10, 12.5 and 15 pg/mL and Controlling for Disease Duration

sNfL	n/N	Odds ratio (95% CI)	p Value	Sensitivity (%)	Specificity (%)
<7.5 pg/mL	27/116	0.14 (0.04–0.45)	<0.001	64.7	52.3
>10 pg/mL	78/116	5.03 (2.02–12.54)	<0.001	66.7	58.5
>12.5 pg/mL	69/116	5.80 (2.45–13.75)	<0.001	72.5	67.7
>15 pg/mL	64/116	6.38 (2.74–14.84)	<0.001	78.4	67.7

Abbreviation: sNfL = serum neurofilament light chain.

^aFingolimod, natalizumab, rituximab, and alemtuzumab.